BD Announces Launch of a Mobile App in Canada to Support Reporting from the BD Veritor™ Plus System for Rapid Antigen Testing

Publish date: May 11, 2021

MISSISSAUGA, ON, 11 May 2021 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the immediate Canadian availability of the ImageMover app, a companion mobile app to the BD Veritor™ Plus System that enables more streamlined management of SARS-CoV-2 antigen testing results, significantly reducing the requirements for manual documentation. The app enables organizations performing point-of-care testing to efficiently capture required demographic details of those being tested, upload and store COVID-19 test results, and report results to appropriate stakeholders.

"The ImageMover app will help resolve the administrative reporting burden for workplaces adopting testing programs and further strengthen the advantages of using a digitally-read test like the BD Veritor™ Plus System," said Ivy Parks, vice president of BD Life Sciences-Integrated Diagnostics Solutions in Canada. "From handheld portability to a simple workflow to a definitive digital readout of results that eliminates human subjectivity and now an automated reporting tool, the BD Veritor™ Plus System provides the simplicity needed for novice testers."

“The availability of a mobile app to support the BD Veritor™ Plus System is welcome news for businesses using this innovative rapid testing system,” said David Wojcik, President & CEO, Mississauga Board of Trade. “Employing technology to increase the ease of use and reduce the manual recording of test results will have a dramatic impact on uptake, reporting of results and efficient contact tracing.”

This is part of an investment in resources to support the deployment of the 11.6 million rapid, point-of-care, SARS-CoV-2 antigen tests procured by the Canadian government for use on the BD Veritor™ Plus System.

Canadian-based bilingual training resources have been put in place to offer one-on-one virtual training sessions for any sites adopting the BD Veritor™ Plus System. Additionally, a dedicated phone support team has been set up to support users of the point-of-care test seven days a week. BD–Canada is also leveraging existing clinical resources, from medical affairs to LEAN health care consultants, to support the implementation of rapid testing in Canada.

“We are ready and willing to provide training tools and offer ongoing support for the implementation of the BD Veritor™ Plus System, helping to ensure successful adoption of these point-of-care tests to protect our community,” said Greg Miziolek, president of BD-Canada.

BD has been on the forefront of the COVID-19 response, providing innovative solutions for immunology research, molecular- and antigen-based diagnostics, devices that aid in therapeutics and injection devices for vaccine administration. The BD manufacturing facility for the global supply of molecular COVID-19 tests run on the BD MAX™ Analyzer is located in Quebec, Canada. Employing over 300 associates, this facility is committed to supporting the local hotspots in Canada and around the world, while continuing to support local economic development.

For more information about the BD Veritor™ Plus System, please visit:


About the BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay is performed on an easy-to-use, portable instrument called the BD Veritor™ Plus Analyzer, that delivers a digital readout of results in approximately 15 minutes. The test uses a mid-nasal swab to collect patient samples, which is less invasive for the patient than nasopharyngeal sample collection.

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay has been authorized by Health Canada under Interim Order. This test is only authorized for the duration of the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19, unless the authorization is terminated or revoked sooner. The SARS-CoV-2 antigen assay has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.


About ImageMover

ImageMover is a medical software company that innovates seamless point-of-care medical workflow software solutions for healthcare professionals and patients. The company's solutions employ an exclusive approach to securely capture and integrate medical data to simplify communication and enhance patient care. For more information, visit or email


Nadia Santoli